[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625301":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":58,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Aron Research Foundation Ets","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Matteo Santoni","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Matteo Santoni, Medical Doctor","CONTACT","+39","matteo.santoni82@gmail.com",[19],{"facility":20,"status":7,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Ospedale di Macerata","Province of Macerata","62100","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],13.45293,43.29789,{"lat":29,"lon":28},[32],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100625301","international-multicentric-retrospective-study-on-the-use-of-evp-as-first-line-therapy-in-patients-with-lamuc-100625301",false,"NCT07420855","International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la\u002FmUC","International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced\u002FMetastatic Urothelial Cancer (ARON-2PLUS)","ARON-2PLUS","Inclusion Criteria:\n\n* Patients aged \\>18years\n* Histologically confirmed diagnosis of la\u002FmUC of upper and\u002For lower urinary tract or histologically confirmed diagnosis of rare GU tumors.\n* Histologically or radiologically confirmed metastatic disease\n* Patients treated with first-line EV+P combination\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of UC\n* Patients without histologically or radiologically confirmed la or mUC","ALL","18 Years",{"count":46,"type":47},361,"ESTIMATED","OBSERVATIONAL","The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced\u002Fmetastatic Urothelial Cancer.\n\nTwo supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.",[51,52],"Locally Advanced or Metastatic Urothelial Cancer","Urothelial Cancer",[54,55,56,57],"urothelial cancer","pembrolizumab","enfortumab vedotin","rare genitourinary tumors","NOT_YET_RECRUITING","2026-02-12",{"date":61,"type":62},"2026-02-19","ACTUAL",{"date":64,"type":47},"2026-02",{"date":66,"type":47},"2030-12",{"name":5,"class":6},1]